We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to... Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. Show more
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management...
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease, on track for Q4 2024 Strengthened leadership team with key appointments:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.23 | 4.32330827068 | 5.32 | 5.68 | 5.08 | 320442 | 5.3090146 | CS |
4 | -0.35 | -5.93220338983 | 5.9 | 6.25 | 4.8 | 462506 | 5.37940902 | CS |
12 | -0.8 | -12.5984251969 | 6.35 | 7.5773 | 4.8 | 609778 | 6.08320283 | CS |
26 | 0.16 | 2.96846011132 | 5.39 | 8.9 | 3.66 | 671361 | 6.19461276 | CS |
52 | -2.25 | -28.8461538462 | 7.8 | 9.065 | 3.66 | 634896 | 6.36865293 | CS |
156 | -10.62 | -65.6771799629 | 16.17 | 43.32 | 3.66 | 693635 | 14.57641431 | CS |
260 | -14.45 | -72.25 | 20 | 45 | 3.66 | 640522 | 16.14239181 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions